References

Trends and cross-country inequalities in schizophrenia from 1990 to 2021, with prediction to 2035: a systematic analysis of the global burden of disease study 2021

10.1186/s12888-025-07273-6 · 2025 · External reference

Unresolved reference

2025 · External reference

Real-world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages

10.1002/wps.70066 · 2026 · External reference

INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia

10.1016/s2215-0366(25)00031-8 · 2025 · External reference

The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: a systematic review and meta analysis

10.1016/j.schres.2009.01.008 · 2009 · External reference

Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors

10.1002/wps.20994 · 2022 · External reference

Comparative effectiveness of antipsychotics in patients with schizophrenia spectrum disorder

10.1001/jamanetworkopen.2024.38358 · 2024 · External reference

Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases

10.1016/s0140-6736(25)02365-7 · 2026 · External reference

Schizophrenia

10.1038/s41572-025-00667-6 · 2025 · External reference

Access to medicines through health systems in low- and middle-income countries

10.1093/heapol/czz119 · 2019 · External reference

New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis

10.1136/bmjment-2023-300759 · 2023 · External reference

Digital mental health: challenges and next steps

10.1136/bmjment-2023-300670 · 2023 · External reference

Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement

10.1136/bmj-2022-070849 · 2022 · External reference

Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology

10.1176/appi.ajp.2016.16050503 · 2017 · External reference

Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis

10.1007/s00406-018-0869-3 · 2018 · External reference

Digital mental health for schizophrenia and other severe mental illnesses: an international consensus on current challenges and potential solutions

10.2196/57155 · 2024 · External reference

Engagement and attrition in digital mental health: current challenges and potential solutions

10.1038/s41746-025-01778-w · 2025 · External reference

Digital health interventions for schizophrenia: setting standards for mental health

10.1016/j.schres.2024.04.013 · 2024 · External reference

Beyond counting clicks: rethinking engagement in digital mental health

10.1192/bjp.2025.10485 · 2025 · External reference

ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi

10.1371/journal.pmed.1004326 · 2024 · External reference

Global mental health research and practice: a decolonial approach

10.1016/s2215-0366(22)00043-8 · 2022 · External reference

The Lancet and colonialism: past, present, and future

10.1016/s0140-6736(24)00102-8 · 2024 · External reference

The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis

10.1016/s2215-0366(22)00304-2 · 2022 · External reference

Antipsychotic dose and efficacy for acute schizophrenia spectrum disorders: an updated systematic review and dose-response meta-analysis

10.1016/j.eclinm.2026.103847 · 2026 · External reference

Data-driven taxonomy for antipsychotic medication: a new classification system

10.1016/j.biopsych.2023.04.004 · 2023 · External reference

A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature

10.1016/j.euroneuro.2015.08.019 · 2015 · External reference

CINeMA: an approach for assessing confidence in the results of a network meta-analysis

10.1371/journal.pmed.1003082 · 2020 · External reference

Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis

10.1016/s0140-6736(19)31135-3 · 2019 · External reference

Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development

10.1016/s2215-0366(23)00262-6 · 2023 · External reference

Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis

10.1016/s2215-0366(19)30416-x · 2020 · External reference

Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-analysis

10.1093/ijnp/pyae052 · 2024 · External reference

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials

10.1097/yic.0000000000000371 · 2021 · External reference

Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: a systematic review and meta-analysis

10.1016/j.euroneuro.2024.11.013 · 2025 · External reference

Efficacy, acceptability and side-effects of oral versus long-acting-injectables antipsychotics: systematic review and network meta-analysis

10.1016/j.euroneuro.2024.03.003 · 2024 · External reference

Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis

10.1002/wps.21089 · 2023 · External reference

Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis

10.1016/j.euroneuro.2018.03.008 · 2018 · External reference

Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses

10.1016/s2215-0366(17)30270-5 · 2017 · External reference

Antipsychotic drugs for elderly patients with schizophrenia: a systematic review and meta-analysis

10.1016/j.euroneuro.2018.09.007 · 2018 · External reference

Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis

10.1016/j.euroneuro.2018.11.1105 · 2019 · External reference

Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis

10.1016/s0140-6736(21)01997-8 · 2022 · External reference

Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data

10.1016/s2215-0366(23)00366-8 · 2024 · External reference

A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia

10.1007/s00406-023-01654-2 · 2024 · External reference

Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis

10.1016/j.eclinm.2025.103291 · 2025 · External reference

Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review

10.1038/s41398-021-01613-2 · 2021 · External reference

Examining the safety profile of clozapine versus other antipsychotics: systematic review and meta-analysis

10.1192/bjp.2025.10421 · 2025 · External reference

Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta-analysis from two nationwide cohorts

10.1002/wps.21316 · 2025 · External reference

Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis

10.1016/j.schres.2021.01.021 · 2021 · External reference

Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)

2017 · External reference

Haloperidol plus promethazine for psychosis-induced aggression

2016 · External reference

Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia

10.1176/appi.ajp.2019.19010034 · 2020 · External reference

Antipsychotic-related prolactin changes: a systematic review and dose-response meta-analysis

10.1007/s40263-025-01218-z · 2025 · External reference

Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis

10.1038/s41380-023-02203-y · 2023 · External reference

Antipsychotic drug dosing and study discontinuation in schizophrenia: a systematic review and dose-response meta-analysis

10.1016/j.euroneuro.2025.02.012 · 2025 · External reference

Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis

2022 · External reference

Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies

10.1016/s2215-0366(21)00039-0 · 2021 · External reference

Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies

10.1001/jamapsychiatry.2019.1702 · 2019 · External reference

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

10.1016/s0140-6736(17)30060-0 · 2017 · External reference

Droperidol for psychosis-induced aggression or agitation

2016 · External reference

Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis

10.1016/s2352-4642(24)00098-1 · 2024 · External reference

Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics

10.1016/j.schres.2016.07.018 · 2016 · External reference

Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis

10.1192/bjp.2023.27 · 2023 · External reference

Antipsychotic augmentation vs monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis

10.1002/wps.20387 · 2017 · External reference

Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis

10.1038/s41386-019-0440-6 · 2019 · External reference

Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors

10.1176/appi.ajp.2017.16121358 · 2017 · External reference

Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials

10.1001/jamapsychiatry.2021.3990 · 2022 · External reference

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia

10.1192/j.eurpsy.2022.11 · 2022 · External reference

Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study

10.1093/schbul/sbab063 · 2021 · External reference

The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis

10.1002/wps.20822 · 2021 · External reference

“Short” versus “long” duration of untreated psychosis in people with first-episode psychosis: a systematic review and meta-analysis of baseline status and follow-up outcomes

10.1093/schbul/sbae201 · 2025 · External reference

A decision-support system to personalize antidepressant treatment in major depressive disorder: a randomized clinical trial

10.1001/jama.2026.1327 · 2026 · External reference

An online evidence-based dictionary of common adverse events of antidepressants: a new tool to empower patients and clinicians in their shared decision-making process

10.1186/s12888-024-05950-6 · 2024 · External reference

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants

10.1002/wps.20972 · 2022 · External reference

The use of long-acting injectables for people with schizophrenia: consensus panel recommendations for overcoming barriers and implementing treatment

10.1007/s40120-025-00838-3 · 2025 · External reference

Loneliness in psychosis: a meta-analytical review

10.1093/schbul/sbx036 · 2018 · External reference

Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: is there a racial difference?

10.1186/1756-0500-1-25 · 2008 · External reference

The apportionment of pharmacogenomic variation: race, ethnicity, and adverse drug reactions

10.18103/mra.v10i9.2986 · 2022 · External reference

Susceptibility of persons with schizophrenia to extreme heat: a critical review of physiological, behavioural, and social factors

10.1016/j.scitotenv.2025.179965 · 2025 · External reference

Medications, epilepsy and climate change: added layers of complexity

10.1002/bcp.70108 · 2025 · External reference

The epidemiology of psychiatric disorders in Africa: a scoping review

10.1016/s2215-0366(21)00009-2 · 2021 · External reference

Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis

10.1016/s2215-0366(24)00314-6 · 2024 · External reference

Global trends in clozapine utilisation between 2014 and 2024: a longitudinal epidemiological study with data from 75 countries

2026 · External reference

Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice

10.1016/j.euroneuro.2024.04.012 · 2024 · External reference

Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis

10.1192/bjp.2025.89 · 2026 · External reference

A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia

10.1007/s40263-022-00932-2 · 2022 · External reference

Education versus screening: the use of capacity to consent tools in psychiatric genomics

10.1136/medethics-2019-105396 · 2020 · External reference

Schizophrenia trials conducted in African countries: a drop of evidence in the ocean of morbidity?

10.1186/1752-4458-6-9 · 2012 · External reference

Antipsychotic medication in sub-Saharan Africa: a systematic literature review

10.1097/jcp.0000000000001282 · 2020 · External reference

Early intervention in psychosis and management of first episode psychosis in low-and lower-middle-income countries: a systematic review

10.1093/schbul/sbae025 · 2024 · External reference

Effect of collaborative care between traditional and faith healers and primary health-care workers on psychosis outcomes in Nigeria and Ghana (COSIMPO): a cluster randomised controlled trial

10.1016/s0140-6736(20)30634-6 · 2020 · External reference

Community study of knowledge of and attitude to mental illness in Nigeria

10.1192/bjp.186.5.436 · 2005 · External reference

Beyond the methodological binary: coproduction as the third pillar of mental health science

10.1136/bmjment-2025-301807 · 2025 · External reference

Democratizing clinical research

10.1038/474277a · 2011 · External reference

Holistic prevention and management of physical health side-effects of psychotropic medication: second report of the Lancet Psychiatry Physical Health Commission

10.1016/s2215-0366(25)00162-2 · 2025 · External reference